Clinical Trial

Managed Access Programs for VAY736, Ianalumab

Available
View on ClinicalTrials.gov →
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to VAY736, ianalumab
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-17; most recent amendment 2026-03-19.
Status change: Temporarily Not Available → Available 2025-12-02
Trial Details
NCT Number NCT07244289
Lead Sponsor Novartis Pharmaceuticals
Conditions Primary Immune Thrombocytopenia, Sjögren's Syndrome
Updated on ClinicalTrials.gov 2026-03-23